Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy
ConclusionUsing clinical trial data, canagliflozin treatment was projected to delay dialysis by approximately 13 years, which could translate to a substantial cost savings. More precise estimates should be investigated with considerations for nonlinear eGFR slope trajectory, competing risks, and patient characteristics.Trial RegistrationClinicalTrials.gov identifier, NCT02065791.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Canagliflozin | Chronic Kidney Disease | Clinical Trials | Diabetes | Dialysis | Endocrinology | Invokana | Kidney Transplant | Kidney Transplantation | Sodium | Transplants | Urology & Nephrology